The most shared features (10) (Figure 2) between the MGMT analysis and the CRT analysis in the local dataset have reported relevance to GBM: ADGRF2 (overexpressed in glioma, regulating proliferation and migration) [44], AHSG (serum level predicts survival in GBM) [45], CRP [46], ME2 (promotes proneural mesenchymal transition) [47], MMP1 (expression upregulated in GBM and associated with decreased survival) [48], Sigle9 (immune evasion, reduced survival) [49], and others which are not yet fully defined: FCGR3A, LAT, and PRTN3 [20]. The gene discussed is ADGRF2P; the disease is glioma.